NeuroDerm Announces Completion of Patient Enrollment and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson’s Disease

- First evaluation of clinical efficacy of ND0612H in advanced Parkinson's patients -

REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM ), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it completed patient enrollment and treatment in trial 006 of ND0612H, the company’s continuously administered levodopa/carbidopa (LD/CD) solution. ND0612H, administered subcutaneously through a belt pump, is designed to deliver steady LD/CD levels to advanced Parkinson's patients with motor fluctuations that cannot be adequately controlled with oral therapy and to become an alternative to treatments with surgical intervention.

Trial 006, a 28-day international, multicenter, parallel-group, single blind (rater-blinded), randomized pilot phase II study, was the first trial to investigate the efficacy, safety, tolerability and pharmacokinetics of two dosing regimens of the high dose version of ND0612 (ND0612H) compared with the baseline oral standard of care. The study enrolled a total of 38 patients with advanced Parkinson’s disease.  Topline results from this trial are expected in the first quarter of 2017.

“The timely completion of the first trial that evaluates the efficacy of ND0612H marks an important milestone in the development of this drug,” said Oded S. Lieberman, PhD, CEO of NeuroDerm. “This trial was designed to reflect the expected clinical usage of ND0612H by advanced Parkinson's patients and to provide critical data on the safety and efficacy of an extended period of therapy. Investigator support for this trial as well as interest by patients was robust, reflecting the current unmet need in treating Parkinson’s disease and the desire for new treatment options. Many advanced Parkinson’s disease patients suffer motor complications that cannot be adequately controlled with current therapy. They face limited treatment options that may require surgical intervention that is associated with possible serious adverse effects and death. NeuroDerm is committed to providing advanced stage patients with a new therapeutic option that will be a safe, simple and effective alternative to current surgical treatments.”

About ND0612 ND0612 is designed to significantly reduce motor complications in Parkinson's disease patients through continuous, subcutaneous delivery of LD/CD solution. Previously completed Phase 2 trials demonstrated that a low dose of ND0612 (ND0612L) maintained steady, therapeutic levodopa plasma concentrations that were associated with major changes in several clinical parameters including "off time" reductions when added to optimal oral standard of care.  A high dose of ND0612 (ND0612H), intended for severe Parkinson's disease patients, was shown to reach even higher levodopa steady plasma levels, indicating that it may provide an effective therapy alternative to current treatments requiring surgery such as deep brain stimulation and LD/CD Intestinal Gel.

About Parkinson's disease Parkinson's disease is a progressive neurodegenerative illness characterized by reduced dopamine in the brain, resulting in a debilitating decrease in the patient's motor and non-motor functions.  Its symptoms, such as trembling in the extremities and face, slowness of movement and impaired balance and coordination, worsen over time and gravely impact the patient's quality of life.  Levodopa is the most effective treatment for Parkinson’s disease.  However, chronic oral levodopa treatment is associated with fluctuations in motor response as result of which, despite the benefits of the drug, patients can experience periods of impaired motor and non-motor functions, also referred to as "off" time.  In addition, mainly as a result of excessive/intermittent oral doses of levodopa aimed at treating the "off" time, some patients experience involuntary movements, or dyskinesia.  The "off" time and dyskinesia affect the majority of levodopa-treated Parkinson's disease patients and can interfere with day-to-day functions, causing patients to become severely disabled.  Current evidence suggests that intermittent dosing with standard oral formulations of levodopa contributes to the development of these motor complications.  By contrast, it has been shown that continuous administration of levodopa can effectively treat motor fluctuations in Parkinson's disease patients without increasing troublesome dyskinesia; however, a convenient route for continuous administration has not been introduced to date.

About NeuroDerm NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration.  The Company has three product candidates in different stages of development which offer a solution for almost every Parkinson’s disease patient from the moderate to the very severe stage of the disease.  The Company has developed a line of levodopa and carbidopa (LD/CD) product candidates administered through small belt pumps that deliver a continuous, controlled dose of LD/CD.  The LD/CD product candidate in low dose and high dose form (ND0612L and ND0612H), are used for the treatment of moderate and advanced Parkinson’s disease patients, respectively, and are delivered subcutaneously.  In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD.  NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.

Forward-Looking Statements This press release contains forward-looking statements, within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties. Such forward-looking statements may include projections regarding our future performance and may be identified by words like "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek" and similar terms or phrases. The forward-looking statements contained in this press release are based on management's current expectations and projections about future events. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the risks provided under "Risk Factors" in our annual report on Form 20-F for the year ended December 31, 2015 filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this press release speaks only as of the date hereof. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

NeuroDerm Contact: Oded S. Lieberman, PhD, CEO oded@neuroderm.com Tel.: +972-8-946 2729; Cell: +1-617-517 6077

U.S. Investor Contact: David Carey Lazar Partners Ltd. dcarey@lazarpartners.com +212-867-1768

U.S. Media Contact: Erich Sandoval Lazar Partners Ltd. esandoval@lazarpartners.com +917-497-2867

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 101

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
Panama City Beach Rentals: Rules Before the Ocean View

Updated Category News Views 49

A postcard-perfect balcony can hide a remarkably expensive rulebook. That is the unglamorous message in Angie Outlaw’s discussion of vacation-property buying in Panama City Beach: the view may sell the unit, but zoning, association documents, insurance and lender terms determine whether the purchase behaves anything like the income-producing asset a buyer pictured. I...

Continue Reading
JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 63

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Radiology Staffing Gap Deepens as Imaging Demand Rises

Updated Category News Views 91

An imaging order does not mean much if nobody is available to read it, and that plain operational fact sits at the center of Medicus Healthcare Solutions' 2026 report on the radiologist shortage. The report's projected gap of 2,450 full-time-equivalent radiologists in 2027 is troubling enough. Its estimate of a 4,130 FTE shortfall by 2032 is the part that should make...

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 92

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading
Misunderstood Brands Bets Small Cans Can Scale Growth

Updated Category News Views 177

A tiny cocktail can is a brutal little test of whether a spirits brand has legs. Misunderstood Brands is putting four 100mL offerings on the shelf just as its Wegmans distribution expands across the East Coast, and that combination matters more than another glossy flavor announcement. The company is trying to turn products people discovered in bars and restaurants into...

Continue Reading
The Hanover Survey Puts Small-Business Trust on Trial

Updated Category News Views 121

A dark storefront can apparently erase goodwill faster than plenty of owners want to admit. The Hanover Insurance Group's 2026 Small Business Pulse Report found that 60% of surveyed consumers would temporarily buy from a competitor if their preferred small business shut unexpectedly. More than half would start looking elsewhere within a week. That is not a cute...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 95

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 108

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
Highway 99 Truck Death Puts Safety Records in Focus

Updated Category News Views 60

A stopped car on a highway shoulder is supposed to be a bad day, not a death sentence. Yet on November 5, 2026, a person helping a relative with a disabled vehicle was killed on northbound Highway 99 in Elk Grove after a commercial tractor-trailer allegedly drifted onto the shoulder, hit both stationary vehicles, and overturned. Northbound lanes were closed for hours. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Work Protective Gear to Enhance Safety and Comfort

Updated Category News Views 209

Revolutionizing Workplace Safety with New Gear Workplace injuries remain a significant concern across various job sites, with issues such as severe cuts and long-lasting knee damage becoming all too common. These challenges not only compromise the well-being of workers but also inflate costs for employers. Many workers often overlook critical personal protective equipment...

Continue Reading
Exploring Innovations in Toxicology at Upcoming ACMT Meeting

Updated Category News Views 380

Innovative Toxicology Research Unveiled at the 2025 ACMT Meeting In an exciting announcement, the American College of Medical Toxicology (ACMT) is gearing up for its 2025 Annual Scientific Meeting and Symposia, set to take place from April 2 to 6 at the Fairmont Hotel in Vancouver. This year promises an inspiring lineup featuring five days filled with groundbreaking...

Continue Reading
ConnectM Technology Solutions' Live Investor Webinar Invitation

Updated Category News Views 77

ConnectM Announces Exclusive Investor Webinar ConnectM Technology Solutions, Inc. (NASDAQ: CNTM), a pioneering technology firm in the electrification economy, is hosting a special investor webinar on March 4, at 4:15 p.m. Eastern Time. This event is a unique opportunity to learn about the company's strategies and insights in a rapidly evolving industry. Discover the...

Continue Reading
Deadline for SelectQuote Investors Approaching Soon

Updated Category News Views 177

Investors Urged to Take Action on SelectQuote Losses Attention investors! If you have experienced financial losses in SelectQuote, now is the time to act. Faruqi & Faruqi, LLP is leading the charge in investigating claims on behalf of investors who may have suffered due to the company's recent developments. Investors are proudly encouraged to reach out if they believe...

Continue Reading
Empowering Girls in Sports: NRPA and Nike's Initiative

Updated Category News Views 486

NRPA and Nike Unite for Gender Equity in Youth Sports The National Recreation and Park Association (NRPA) has joined forces with Nike, highlighting a shared commitment to advancing gender equity in youth sports. This partnership emphasizes the necessity of equitable access to sporting opportunities for all youth, especially girls, to ensure they thrive in their...

Continue Reading